Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.60 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | GLA | P06280 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL388418 | 0.89 | BAZ2B (0.61) | BAZ2BBAZ2AKDM4EGAAGLA | |
| SCHEMBL12344059 | 0.85 | BAZ2B (0.56) | BAZ2BBAZ2AKDM4EGAAGLA | |
| SCHEMBL390410 | 0.83 | BAZ2B (0.54) | BAZ2BBAZ2AKDM4EGAAGLA | |
| SCHEMBL1516488 | 0.78 | BRD4 (0.39) | BAZ2BBAZ2AGAATSHRKMT2A | |
| SCHEMBL392754 | 0.75 | BAZ2B (1.00) | BAZ2BBAZ2AKDM4EGAAGLA | |
| SCHEMBL14643568 | 0.74 | BAZ2B (0.51) | BAZ2BBAZ2AKDM4EGAAGLA | |
| SCHEMBL17156825 | 0.74 | BAZ2B (0.51) | BAZ2BBAZ2AKDM4EGAAALDH1A1 | |
| SCHEMBL6779742 | 0.73 | BAZ2B (0.54) | BAZ2BBAZ2AKDM4EGAAGLA | |
| SCHEMBL29248873 | 0.73 | BAZ2B (0.50) | BAZ2BBAZ2AKDM4EGAAGLA | |
| SCHEMBL17156702 | 0.73 | BAZ2B (0.50) | BAZ2BBAZ2AKDM4EGAAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160271122-A1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | ARDEA BIOSCIENCES, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160271122-A1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | ARDEA BIOSCIENCES, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160271122-A1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | ARDEA BIOSCIENCES, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20150267258-A1 | BIOMARKERS FOR DETERMINING EFFECTIVE RESPONSE OF TREATMENTS OF HEPATOCELLULAR CARCINOMA (HCC) PATIENTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150267258-A1 | BIOMARKERS FOR DETERMINING EFFECTIVE RESPONSE OF TREATMENTS OF HEPATOCELLULAR CARCINOMA (HCC) PATIENTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150267258-A1 | BIOMARKERS FOR DETERMINING EFFECTIVE RESPONSE OF TREATMENTS OF HEPATOCELLULAR CARCINOMA (HCC) PATIENTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-09-24 | — | — | US | disclosed |
| US-9095581-B2 | Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof | ARDEA BIOSCIENCES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9095581-B2 | Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof | ARDEA BIOSCIENCES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9095581-B2 | Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof | ARDEA BIOSCIENCES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| EP-2854779-A1 | BIOMARKERS FOR DETERMINING EFFECTIVE RESPONSE OF TREATMENTS OF HEPATOCELLULAR CARCINOMA (HCC) PATIENTS | Bayer Pharma Aktiengesellschaft (DE) | 2015-04-08 | — | — | EP | disclosed |
| WO-2007121481-A2 | PYRIDONE SULFONAMIDES AND PYRIDONE SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070244164-A1 | PYRIDONE SULFONAMIDES AND PYRIDONE SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244164-A1 | PYRIDONE SULFONAMIDES AND PYRIDONE SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244164-A1 | PYRIDONE SULFONAMIDES AND PYRIDONE SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-05-17 | — | — | US | disclosed |
| EP-1682138-A4 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1682138-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050256123-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-11-17 | — | — | US | disclosed |
| US-20050250782-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-11-10 | — | — | US | disclosed |
| WO-2005051301-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | BAZ2B 2035/4885BAZ2A 2292/4885KDM4E 665/4885 |
| US-20050250782-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | BAZ2B 2141/4885BAZ2A 2301/4885KDM4E 889/4885 |
| US-20160271122-A1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | BRAF, RAF1, NRAS | BAZ2B 641/4885BAZ2A 646/4885KDM4E 2509/4885 |
| US-20050256123-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | BAZ2B 1945/4885BAZ2A 2062/4885KDM4E 728/4885 |
| US-20150267258-A1 | BIOMARKERS FOR DETERMINING EFFECTIVE RESPONSE OF TREATMENTS OF HEPATOCELLULAR CARCINOMA (HCC) PATIENTS | NRAS, KRAS, TP53 | BAZ2B 1493/4885BAZ2A 1837/4885KDM4E 2492/4885 |
| US-20070244164-A1 | PYRIDONE SULFONAMIDES AND PYRIDONE SULFAMIDES AS MEK INHIBITORS | BRAF, PDXK, MAP3K20 | BAZ2B 927/4885BAZ2A 887/4885KDM4E 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.